Medicinal Chemistry Journal of Medicinal Chemistry
Hydrazide-based degraders hit HDAC3 selectively without killing cells
- Built from the HDAC3-preferential inhibitor FL-007, comparing two linker exit vectors; the best series keeps only modest class I enzyme inhibition yet degrades HDAC3 selectively.
- Degradation was confirmed by immunoblot and HiBiT/LgBiT reporter assays in several cancer lines, with high maximal depletion.
- No cytotoxicity at high doses, even in non-cancerous cells; HDAC3 loss only partly re-sensitized cisplatin-resistant cells, tied to increased H3 acetylation and p21.
The interesting puzzle is where the selectivity originates. Alkyl hydrazides bind HDAC1, 2 and 3 alike, so the discrimination probably arises in the ternary complex, through how well ubiquitination geometry fits each isoform. A non-degrading hydrazide control, a ligase-dead analogue and HDAC1/2 proteomics would separate these explanations and show how wide the window really is.
Paper: Journal of Medicinal Chemistry ↗ Discovery of Potent and Non-cytotoxic HDAC3-Selective Degraders Featuring a Propyl Hydrazide Zinc-Binding Group